



INVESTOR CALL

LIVE SESSION WITH THE
CS MEDICA TEAM

Monday 29 August ,2022

10-10.30 AM CET



AGENDA

Address the frequent topics of interest

Q&A from our investors, within the MAR rules

Details on the latest press release - new findings of the Psoriasis clinical trial



ADDRESSING THE FREQUENT TOPICS OF INTEREST

Share development

Realism

Funding Information


China



ADDRESSING THE FREQUENT TOPICS OF INTEREST



Share development



Higher Turnover Rate of the Free Float + increasing amounts of Shareholders & Volume

Shareholders NON + AVA

January 22, 694

15 August 22: 963

+39%

25 August 22: 1.701

+77%

Free float, average

CS MEDICA 14,37%

Spotlight DK 41,56%

First North DK 32,76%

Circulation free float

CS MEDICA 128,10%

Spotlight DK 52,46%

First North DK. 34,16%



Marketing's campaign initiated in DK & SE


ADDRESSING THE FREQUENT TOPICS OF INTEREST



Realism

Groundbreaking discovery in the natural cannabinoid CBD's activity

CBD Activity awareness timeline



ADDRESSING THE FREQUENT TOPICS OF INTEREST

CANNASEN® CBD
SCIENCE IS IN OUR NATURE



Funding Information

CSMEDICA

WHO WE ARE INVESTOR NEWS ROOM CORPORATE GOVERNANCE CONTACT US



Press releases

All NEWS NON REGULATORY PRESS RELEASE REGULATORY VIDEO

August 28, 2022 NON REGULATORY NEWS
CS MEDICA A/S change date for live-streamed Q&A Event to August 29th at 10:00 – 11:00 CET

[Read more](#)

August 26, 2022 NON REGULATORY NEWS
CS MEDICA A/S invites to a live-streamed Q&A Event on September 2nd at 14:00 – 14:30 CEST

[Read more](#)

August 26, 2022 REGULATORY
Last day of trading in warrants of series TO 1 is 30 August 2022

[Read more](#)

August 25, 2022 REGULATORY
CS MEDICA A/S signs LOI with investor about a directed issue of 60 MDKK at a share price of DKK 31.50 per share

[Read more](#)

All press releases

Regulatory

Non Regulatory

News articles & Media

Videos

Image gallery

Media contact

Newsletter

First Name

Name

CSMEDICA

news.csmica.com CS MEDICA A/S

US/UK/Canada

Share



About Us

CS Medica is a Danish medico company committed to developing and commercializing evidence-based and innovative medical devices within pain relief and care taking. The company is exploring and harnessing the potential of substances in the Cannabis sativa L. plant and related to its cannabinoid technology. CS Medica's vision is to become a world-leading Manufacturer of medical devices.

[MORE](#)

Quotes

"We are proud to announce, that we finally made it to the pharmacies, with agreement signed with two of the three leading pharmacy chains in Denmark. We will use and optimize this new position in the market by accelerating our listings and built brand stores on the growing players within the online pharmacy channel."

—Lone Henriksen, CEO CS MEDICA A/S
"We are very proud to be able to become the first legal CBD brand to enter the Israeli market, notably as Israel is one of the global leaders within the area of CBD and Cannabis research. We look very much forward to our collaboration with our strong partner in Israel, Forbe HealthCare Ltd., and we are confident

Enter your search here...


SEARCH

All Pick a time period

Tags (0 Active)

CS MEDICA A/S: CS MEDICA reports Proof of Concept in the results from the clinical trial on NGP-01 (CANNASEN® CBD Psoriasis Gel) against placebo

MON, AUG 28, 2022 08:45 CET



CS MEDICA ("CS MEDICA" or the "Company") announces today that the final efficacy analysis in their clinical trial of CANNASEN® CBD Psoriasis Gel (NGP-01) met all the trial's primary and secondary efficacy

endpoints. Analysis of the data confirms that CANNASEN® CBD Psoriasis Gel (NGP-01) has efficacy in reducing skin pain, itch, redness, scaling, and the reduction of psoriasis attack of participants with mild-to-moderate psoriasis.

The clinical trial data show that the CANNASEN® CBD Psoriasis Gel (NGP-01) shows no adverse effects and is well tolerated and safe. No negative issues have been



CS MEDICA A/S change date for live-streamed Q&A Event to August 29th at 10:00 – 11:00 CET

SUN, AUG 28, 2022 16:00 CET
CS MEDICA A/S ("CS MEDICA" or the "Company") announces today that the company has decided to bring forward their live-streamed Event to Monday 29th of August at 10:00-11:00 CET.

Intensifying the focus on operations and market has resulted in several

CS MEDICA A/S invites to a live-streamed Q&A Event on September 2nd at 14:00 – 14:30 CEST


FRI, AUG 26, 2022 14:35 CET
CS MEDICA A/S ("CS MEDICA" or the "Company") announces today that the company invites investors, brokers, analysts, and media to a live-streamed Event Friday the 2nd of September at 14:00 CEST.

CS MEDICA is currently receiving a lot of questions regarding the latest

Subscribe



Media



[MORE](#)

ADDRESSING THE FREQUENT TOPICS OF INTEREST



China Investor

27 & 28.01.2020

CS Medica's daughter company Galaxa Pharma ApS participate and present at Cannabis investor Summit – held in Odense by Invest in Odense

16.08.2021



Derek Light, Special advisor- Life Sciences, Invest in Denmark, Ministry of Foreign affairs

Publish on his LinkedIn profil that CS Medica are the third IPO in the Danish medical cannabis industry! [LINK](#)

21.09.2021

Ulrik Nielsen, Investment Consultant, Invest in Odense, contacts CS Medica, as a Chinese investor group, who recently had invested in another Cannabis Company in DK, are very interested in establishing a distributor agreement with CS Medica for Asia and investment in the company. The contact to a professional advisor for China is established.

28.10.2021

First NDA is signed with Asian potential investor

28.04.2022

First distribution agreement in Asia with Chinese based CBF is signed, established by the professional advisor for China. [PM LINK](#)

20.05.2022

From PM on Q2 report: financial notification regarding securing of liquidity balance

Thursday 18.08.2022

Press release - CS Medica intensify the dialog with potential investor regarding a Direct issue, on a share price goal at of 31,50 DKK

Thursday 25.08.2022

Press release - CS Medica signs Lol with investor about direct issue of 60 MDKK at a share price of 31,50 DKK per share



Q&A





Questions sent from investors

How have you negotiated the direct issue with the Chinese company?

How did it come to be that particular company and China?

How long do you think it takes for dd and approved by Chinese authorities?

When do you get access to the 60 MDKK according to your assessment if all requirements are met?

Which investment bank acted as advisor?

Do you consider that there is any risk in having a major Chinese owner when entering the American market?

Lots of rumors surrounding Diaz and the Instagram account Aktiethjuven right now. What has Diaz concretely brought to CS since they came in as an IR partner? What does the collaboration look like right now?

Were you aware of the connection between Diaz and Aktietjuven?



Psoriasis findings



Clinical Study Results on CANNASEN[®] CBD Psoriasis Gel

A double blind, randomized, parallel group study to evaluate efficacy and safety of NGP-01 gel against placebo in the treatment of mild to moderate Psoriasis.
The final objective analysis is based on 60 cases of mild-to-moderate psoriasis.

Primary objective:

The primary objective is to study the relief in skin pain, and itchiness associated with Psoriasis and reduction of the area of psoriasis attach.
To evaluate the efficacy of NGP-01 GEL when administered to adult subjects with mild-to-moderate plaque psoriasis.



Secondary Objective:

The secondary objective is to study the reduction in redness and scaling of skin.
To evaluate the safety of NGP-01 GEL when administered to adult subjects with mild-to-moderate plaque psoriasis
To evaluate the tolerability of NGP-01 GEL when administered to adult subjects with mild-to-moderate plaque psoriasis.

Study Results:

The median Quality of life questionnaire (EQ-5D by Euro QOL) score was significantly reduced in the treatment group, meaning that the Quality of life for the participants was increased for the participants using the CANNASEN[®] CBD Psoriasis Gel. This is correspondent to the results of PASI-, NRS-, sPGA-Induration-, sPGA-Erythema-, sPGA-Scaling score and the SGA value, which all scores/values indicating pain or discomfort were significantly reduced.

Increased Quality of Life




Study Design

This study was performed in accordance with ICH E6 R2, Schedule-Y (2017) and Ethical Principles as per the Declaration of Helsinki (2013) including archiving of all the essential documents.

Screening Period

13-Week Treatment Period



Screening
Up to Day -30

Visit 0

Baseline
Day 0

Visit 1

Weeks 1, 2, 4, 6, 9 and 11
Days 7,15, 30, 45,60,75 (± 2)

Visits 2 - 7

End of Treatment
Week 13
Day 90 (± 2)

Visit 8



THANK YOU

